News – Page 809 – Endpoints News

That 'historic breakthrough' hyped by Trump and Hahn? The NIH isn't impressed

5 years ago

Carlyle Group injects $260M into a leading cardio player in China, grabbing a seat at the deals table

5 years ago

News briefing: Novartis hands off NASH drug to biotech collaborator, also plans to build new Basel production unit

5 years ago

Wheeling and dealing his way to a cancer drug pipeline, Gilead’s Dan O’Day crafts a rich, $805M deal to bag a ...

5 years ago

As fears of a politically-motivated vaccine EUA grow, Eric Topol delivers an ultimatum to commissioner Hahn: Stand up ...

5 years ago

In the footsteps of AstraZeneca, Novartis commits to carbon-neutral supply chain by 2030

5 years ago

Covid-19 roundup: AstraZeneca launches 3rd US PhIII vaccine study with a vow to avoid 'cutting corners'

5 years ago

Canadian biotech to discontinue omega-3 program after second PhIII fails on significant triglyceride reduction

5 years ago

Lumen Bioscience reels in $16M Series B to 'democratize' biologics

5 years ago

Sanofi, Regeneron hit final nail on the IL-6 repurposing coffin as Kevzara fails PhIII

5 years ago

FDA releases PDUFA VI program report on combination products

5 years ago

Gene therapy upstart recruits more ex-AveXis talent; I-Mab reveals first-half results

5 years ago

Novartis says its Soliris add-on might be able to replace the Alexion drug altogether. But is it too late?

5 years ago

A three-year experiment comes to an end, as Ionis reabsorbs Akcea for $500M

5 years ago

Sold for pennies, Unum gets one last shot at redemption

5 years ago

AstraZeneca looks to widen its lead over SGLT2 rivals with another round of landmark data

5 years ago

GSK, Vir barrel into a fast PhII/III for their lead Covid-19 antibody, chasing a moving target with quick OK in sight

5 years ago

New analysis shows inclisiran consistency in LDL-C reduction as Novartis readies for FDA decision

5 years ago

With biopharma IPOs surging, GoodRx guns for $750M raise

5 years ago

Unfazed by slow rollout, Nestlé buys out Aimmune and its peanut allergy med for $2.6B

5 years ago

Covid-19 roundup: Most Americans worry politics is put before science amid vaccine rush; Daiichi Sankyo furthers mRNA ...

5 years ago

Akcea shows off what Novartis missed and what Pfizer gained, offering more details on PhII cardio data

5 years ago

Paul Hudson is more confident in Sanofi's ability to produce a Covid-19 vaccine — report

5 years ago

FDA commissioner Hahn ousts agency’s new chief spokesperson as plasma controversy continues to smolder

5 years ago

First page Previous page 806 807 808809810 811 812 Next page Last page